Sektion Experimentelle und Translationale Kopf-Hals Onkologie
Head and neck cancers (HNCs) are among the most frequent and destructive human cancers worldwide, causing considerable morbidity and mortality. Most HNCs are diagnosed as squamous cell carcinoma (HNSCC) and are unexpectedly heterogeneous in nature considering cellular, molecular and clinical traits. Main etiological risk factors are tobacco use, extensive alcohol consumption and infection with high-risk human papillomavirus (HPV), in particular HPV16. As for many other solid cancers, the multistep pathogenesis of HNCs is characterized by the accumulation of genetic and epigenetic alterations and resembles a tightly orchestrated balance between immune effector response and tolerance. Hence, the tumor immune microenvironment (TIME) of individual HNC is rather heterogeneous and characterized by a broad spectrum of qualitative and quantitative differences in immune cell populations.
Despite numerous advances in the diagnosis and therapy, consisting of surgery, radio- and chemotherapy, the prognosis of HNC patients has only marginally improved during the past decades and a substantial proportion of HNC patients suffer from locoregional relapse or distant metastasis. For patients with recurrent or metastatic disease the armamentarium of systemic anti-cancer modalities and innovative local approaches continues to grow, but the overall survival remains dismal and is still unsatisfactory. In the past decade, immunotherapy based on immune checkpoint inhibition (ICI) has become an essential pillar for cancer treatment and now represents the standard of care for most human cancers, including HNC. However, the response rate remains low and only a small subset of HNC patients achieves a durable clinical benefit. An urgent medical need is the establishment of accurate response predictors, which is handicapped by the growing body of cellular, molecular, systemic, and clinical variables that modify the complex nature of an effective anti-tumor immune response.
Main objectives of our research program focus on cellular and molecular processes in the pathogenesis of head and neck cancer as well as underlying principles of intrinsic and acquired treatment resistance and cancer cell dissemination. Of particular interest are gene regulatory networks and signaling pathways that modulate the mutual crosstalk between cancer cells and components of the tumor microenvironment, including the immune and nervous systems.
Our vision is a more effective and less toxic treatment of HNC patients by the establishment of predictive and prognostic risk models and the identification of vulnerabilities for molecularly stratified subgroups at a higher risk for treatment failure.
Our experimental and analytical portfolio consists of prospective and retrospective cohort studies and biospecimens derived thereof, integrative analysis of multi-omics data utilizing well-established computational workflows and bioinformatics, establishment and analysis of pre-clinical models (e.g. mouse models and ex vivo cultures) as proof-of-concept studies for innovative therapeutic strategies, and 2D as well as 3D cell culture and co-culture models to address basic scientific concepts.
Group Members
Section Head
Group Leaders
Dr. med. Benjamin Freytag
Group Leader
(Sektion Experimentelle und Translationale Kopf-Hals-Onkologie)
Postdocs
Postdocs
-
Priv.-Doz. Dr. med. Dr. med. dent Julius Moratin
Facharzt für Mund-Kiefer-Gesichtschirurgie
Fachzahnarzt für Oralchirurgie
Plastische und Ästhetische Operationen -
Dr. med. Wiebke Seidel
-
Dr. med. Dr. med. dent. Karl Semmelmayer
Arzt und Zahnarzt
-
Dr. med. dent. Sonja Steen
Ärztin und Zahnärztin
PhD/MD Students
Research Technician
Research Technician
Alumni
Alumnae und Alumni
-
Annette Affolter
-
Pilar Bayo-Zaera
-
Bianca de Bem Prunes
-
Leonie Faller
-
Bohai Feng
-
Verena Friebe
-
Johanna Gaß
-
Babitha George
-
Christiane Gotzian
-
Dr. Jennifer Grünow
-
Steffen Homann
-
Dominik Horn
-
Kathrin Jacob
-
Adriana Jou
-
Natalia Koerich Laureano
-
Markus Kolb
-
Efterpi Kostareli
-
Nele Kreycy
-
Alexandra Leipold
-
Sonja Ludwig
-
Sophie Mainitz
-
Regina Mark
-
Britta Molfenter
-
Marie-France Muller
-
Andrè Nollert
-
Natalie Orthmann
-
Dr. med. Tillmann Pompecki
-
Chao Rong
-
Katrin Schmitt
-
Carola Schrader
-
Matthias Schrittenlocher
-
Julia Schwärzler
-
Sarika Sharma
-
Ingeborg Vogt
-
Sonja Weber
-
Sebastian Weißfuß
-
Christina Zühlke
Research Projects
Publications
2022
TREM2 Is Associated with Advanced Stages and Inferior Prognosis in Oral Squamous Cell Carcinoma. Struckmeier AK, Radermacher A, Fehrenz M, Alansary D, Wartenberg P, Wagner M, Scheller A, Hess J, Moratin J, Freudlsperger C, Hoffmann J, Thurner L, Roemer K, Freier K, Horn D. Cancers (Basel). 2022 Sep 24;14(19):4635. doi: 10.3390/cancers14194635.
IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma. Struckmeier AK, Radermacher A, Fehrenz M, Bellin T, Alansary D, Wartenberg P, Boehm U, Wagner M, Scheller A, Hess J, Moratin J, Freudlsperger C, Hoffmann J, Thurner L, Roemer K, Freier K, Horn D. J Cancer Res Clin Oncol. 2022 Aug 13. doi: 10.1007/s00432-022-04277-7. Online ahead of print.
Specific Targeting of Antiapoptotic Bcl-2 Proteins as a Radiosensitizing Approach in Solid Tumors. Sobol B, Azzam Nieto O, Eberlein EL, Scherr AL, Ismail L, Kessler A, Nader L, Schwab M, Hoffmeister P, Schmitt N, Jäger D, Welte S, Seidensaal K, Christopoulos P, Heilig C, Kriegsmann K, Fröhling S, Kriegsmann M, Hess J, Köhler BC. Int J Mol Sci. 2022 Jul 16;23(14):7850. doi: 10.3390/ijms23147850.
Human Mesenchymal Stromal Cells Do Not Cause Radioprotection of Head-and-Neck Squamous Cell Carcinoma. Rühle A, Lies M, Strack M, Perez RL, Bieber B, Thomsen AR, Bronsert P, Huber PE, Hess J, Knopf A, Wuchter P, Grosu AL, Nicolay NH. Int J Mol Sci. 2022 Jul 12;23(14):7689. doi: 10.3390/ijms23147689.
Mitochondrial RNA modifications shape metabolic plasticity in metastasis. Delaunay S, Pascual G, Feng B, Klann K, Behm M, Hotz-Wagenblatt A, Richter K, Zaoui K, Herpel E, Münch C, Dietmann S, Hess J, Benitah SA, Frye M. Nature. 2022 Jul;607(7919):593-603. doi: 10.1038/s41586-022-04898-5. Epub 2022 Jun 29.
HPV8 Reverses the Transcriptional Output in Lrig1 Positive Cells to Drive Skin Tumorigenesis. Syed AS, Marcuzzi GP, Miller-Lazic D, Hess J, Hufbauer M, Akgül B. Cancers (Basel). 2022 Mar 25;14(7):1662. doi: 10.3390/cancers14071662.
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer. Prasad M, Zorea J, Jagadeeshan S, Shnerb AB, Mathukkada S, Bouaoud J, Michon L, Novoplansky O, Badarni M, Cohen L, Yegodayev KM, Tzadok S, Rotblat B, Brezina L, Mock A, Karabajakian A, Fayette J, Cohen I, Cooks T, Allon I, Dimitstein O, Joshua B, Kong D, Voronov E, Scaltriti M, Carmi Y, Conde-Lopez C, Hess J, Kurth I, Morris LGT, Saintigny P, Elkabets M. J Immunother Cancer. 2022 Mar;10(3):e003917. doi: 10.1136/jitc-2021-003917.
The role of tumor acidification in aggressiveness, cell dissemination and treatment resistance of oral squamous cell carcinoma. de Bem Prunes B, Nunes JS, da Silva VP, Laureano NK, Gonçalves DR, Machado IS, Barbosa S, Lamers ML, Rados PV, Kurth I, Hess J, Jou A, Visioli F. Life Sci. 2022 Jan 1;288:120163. doi: 10.1016/j.lfs.2021.120163.
Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy. Tawk B, Wirkner U, Schwager C, Rein K, Zaoui K, Federspil PA, Adeberg S, Linge A, Ganswindt U, Hess J, Unger K, Tinhofer I, Budach V, Lohaus F, Krause M, Guberina M, Stuschke M, Balermpas P, Rödel C, Grosu AL, Schäfer H, Zips D, Combs SE, Pigorsch S, Zitzelsberger H, Baumeister P, Kirchner T, Bewerunge-Hudler M, Weichert W, Hess J, Herpel E, Belka C, Baumann M, Debus J, Abdollahi A; DKTK-ROG. Int J Cancer. 2022 Feb 15;150(4):603-616. doi: 10.1002/ijc.33842.
2021
Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity. Feng B, Wang K, Herpel E, Plath M, Weichert W, Freier K, Zaoui K, Hess J. Cancers (Basel). 2021 Oct 15;13(20):5182. doi: 10.3390/cancers13205182.
Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers. Moratin J, Mock A, Obradovic S, Metzger K, Flechtenmacher C, Zaoui K, Fröhling S, Jäger D, Krauss J, Hoffmann J, Freier K, Horn D, Hess J, Freudlsperger C. Front Oncol. 2021 Jul 29;11:712944. doi: 10.3389/fonc.2021.712944. eCollection 2021.
Establishment of a Plasticity-Associated Risk Model Based on a SOX2- and SOX9-Related Gene Set in Head and Neck Squamous Cell Carcinoma. Khorani K, Schwaerzler J, Burkart S, Kurth I, Holzinger D, Flechtenmacher C, Plinkert PK, Zaoui K, Hess J. Mol Cancer Res. 2021 Oct;19(10):1676-1687. doi: 10.1158/1541-7786.MCR-21-0066.
JUNB suppresses distant metastasis by influencing the initial metastatic stage. Wutschka J, Kast B, Sator-Schmitt M, Appak-Baskoy S, Hess J, Sinn HP, Angel P, Schorpp-Kistner M. Clin Exp Metastasis. 2021 Aug;38(4):411-423. doi: 10.1007/s10585-021-10108-9.
EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers. Mock A, Plath M, Moratin J, Tapken MJ, Jäger D, Krauss J, Fröhling S, Hess J, Zaoui K. Front Oncol. 2021 Jun 11;11:678966. doi: 10.3389/fonc.2021.678966. eCollection 2021.
Immune-Related Mutational Landscape and Gene Signatures: Prognostic Value and Therapeutic Impact for Head and Neck Cancer. Feng B, Hess J. Cancers (Basel). 2021 Mar 8;13(5):1162. doi: 10.3390/cancers13051162.
Ubiquitin Carboxyl-Terminal Hydrolases and Human Malignancies: The Novel Prognostic and Therapeutic Implications for Head and Neck Cancer. Rong C, Zhou R, Wan S, Su D, Wang SL, Hess J. Front Oncol. 2021 Jan 29;10:592501. doi: 10.3389/fonc.2020.592501. eCollection 2020.
Unraveling most abundant mutational signatures in head and neck cancer. Plath M, Gass J, Hlevnjak M, Li Q, Feng B, Hostench XP, Bieg M, Schroeder L, Holzinger D, Zapatka M, Freier K, Weichert W, Hess J, Zaoui K. Int J Cancer. 2021 Jan 1;148(1):115-127. doi: 10.1002/ijc.33297.
A six-gene expression signature related to angiolymphatic invasion is associated with poor survival in laryngeal squamous cell carcinoma. Metzger K, Moratin J, Freier K, Hoffmann J, Zaoui K, Plath M, Stögbauer F, Freudlsperger C, Hess J, Horn D. Eur Arch Otorhinolaryngol. 2021 Apr;278(4):1199-1207. doi: 10.1007/s00405-020-06214-1.
2020
Organotypic Co-Cultures as a Novel 3D Model for Head and Neck Squamous Cell Carcinoma. Engelmann L, Thierauf J, Koerich Laureano N, Stark HJ, Prigge ES, Horn D, Freier K, Grabe N, Rong C, Federspil P, Zaoui K, Plinkert PK, Rotter N, von Knebel Doeberitz M, Hess J, Affolter A. Cancers (Basel). 2020 Aug 18;12(8):2330. doi: 10.3390/cancers12082330.
Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC. Rong C, Muller MF, Xiang F, Jensen A, Weichert W, Major G, Plinkert PK, Hess J, Affolter A. Br J Cancer. 2020 Jul;123(2):288-297. doi: 10.1038/s41416-020-0892-9.
Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer. Feng B, Shen Y, Pastor Hostench X, Bieg M, Plath M, Ishaque N, Eils R, Freier K, Weichert W, Zaoui K, Hess J. Clin Cancer Res. 2020 Jul 15;26(14):3616-3628. doi: 10.1158/1078-0432.CCR-19-3997.
The transcription factor FOXM1 regulates the balance between proliferation and aberrant differentiation in head and neck squamous cell carcinoma. Roh V, Hiou-Feige A, Misetic V, Rivals JP, Sponarova J, Teh MT, Ferreira Lopes S, Truan Z, Mermod M, Monnier Y, Hess J, Tolstonog GV, Simon C. J Pathol. 2020 Jan;250(1):107-119. doi: 10.1002/path.5342.
2019
Absence of disruptive TP53 mutations in high-risk human papillomavirus-driven neck squamous cell carcinoma of unknown primary. Boscolo-Rizzo P, Schroeder L, Sacchetto V, Holzinger D, Da Mosto MC, Tirelli G, Dal Cin E, Mantovani M, Menegaldo A, Del Mistro A, Romeo S, Dei Tos AP, Niero M, Rigo S, Dyckhoff G, Hess J, Alemany L, Quer M, León X, Polesel J, Pawlita M, Bertorelle R. Head Neck. 2019 Nov;41(11):3833-3841. doi: 10.1002/hed.25915.
Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer. Schmitt K, Molfenter B, Laureano NK, Tawk B, Bieg M, Hostench XP, Weichenhan D, Ullrich ND, Shang V, Richter D, Stögbauer F, Schroeder L, de Bem Prunes B, Visioli F, Rados PV, Jou A, Plath M, Federspil PA, Thierauf J, Döscher J, Weissinger SE, Hoffmann TK, Wagner S, Wittekindt C, Ishaque N, Eils R, Klussmann JP, Holzinger D, Plass C, Abdollahi A, Freier K, Weichert W, Zaoui K, Hess J. Int J Cancer. 2019 Dec 15;145(12):3299-3310. doi: 10.1002/ijc.32481.
Differential Activation of ERK Signaling in HPV-Related Oropharyngeal Squamous Cell Carcinoma. Rong C, Muller M, Flechtenmacher C, Holzinger D, Dyckhoff G, Bulut OC, Horn D, Plinkert P, Hess J, Affolter A. Cancers (Basel). 2019 Apr 25;11(4):584. doi: 10.3390/cancers11040584.
Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. Thierauf J, Ramamurthy N, Jo VY, Robinson H, Frazier RP, Gonzalez J, Pacula M, Dominguez Meneses E, Nose V, Nardi V, Dias-Santagata D, Le LP, Lin DT, Faquin WC, Wirth LJ, Hess J, Iafrate AJ, Lennerz JK. Oncologist. 2019 Oct;24(10):1356-1367. doi: 10.1634/theoncologist.2018-0515.
Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma. Moratin J, Metzger K, Safaltin A, Herpel E, Hoffmann J, Freier K, Hess J, Horn D. Head Neck. 2019 Aug;41(8):2484-2491. doi: 10.1002/hed.25713.
Cortactin expression: Association with disease progression and survival in oral squamous cell carcinoma. Horn D, Gross M, Dyckhoff G, Fuchs J, Grabe N, Weichert W, Herpel E, Herold-Mende C, Lichter P, Hoffmann J, Hess J, Freier K. Head Neck. 2018 Dec;40(12):2685-2694. doi: 10.1002/hed.25515.
2018
Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity. De Vita E, Schüler P, Lovell S, Lohbeck J, Kullmann S, Rabinovich E, Sananes A, Heßling B, Hamon V, Papo N, Hess J, Tate EW, Gunkel N, Miller AK. J Med Chem. 2018 Oct 11;61(19):8859-8874. doi: 10.1021/acs.jmedchem.8b01106.
Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage. Thierauf J, Weissinger SE, Veit JA, Affolter A, Laureano NK, Beutner D, Heiduschka G, Kadletz L, Meyer M, Quaas A, Plinkert P, Hoffmann TK, Hess J. PLoS One. 2018 Mar 29;13(3):e0194989. doi: 10.1371/journal.pone.0194989. eCollection 2018.
Estrogen Receptor Signaling in Radiotherapy: From Molecular Mechanisms to Clinical Studies. Rong C, Meinert ÉFRC, Hess J. Int J Mol Sci. 2018 Mar 2;19(3):713. doi: 10.3390/ijms19030713.
2017
Upregulation of pAKT(Ser473) expression in progression of HPV-positive oropharyngeal squamous cell carcinoma. Horn D, Freudlsperger C, Holzinger D, Kunzmann K, Plinkert P, Dyckhoff G, Hoffmann J, Freier K, Hess J. Head Neck. 2017 Dec;39(12):2397-2405. doi: 10.1002/hed.24910.
Epithelial-to-Mesenchymal Transition in the Pathogenesis and Therapy of Head and Neck Cancer. Thierauf J, Veit JA, Hess J. Cancers (Basel). 2017 Jul 3;9(7):76. doi: 10.3390/cancers9070076.
Glyoxalase 1 expression is associated with an unfavorable prognosis of oropharyngeal squamous cell carcinoma. Kreycy N, Gotzian C, Fleming T, Flechtenmacher C, Grabe N, Plinkert P, Hess J, Zaoui K. BMC Cancer. 2017 May 26;17(1):382. doi: 10.1186/s12885-017-3367-5.
Human papillomavirus as prognostic marker with rising prevalence in neck squamous cell carcinoma of unknown primary: A retrospective multicentre study. Schroeder L, Boscolo-Rizzo P, Dal Cin E, Romeo S, Baboci L, Dyckhoff G, Hess J, Lucena-Porcel C, Byl A, Becker N, Alemany L, Castellsagué X, Quer M, León X, Wiesenfarth M, Pawlita M, Holzinger D. Eur J Cancer. 2017 Mar;74:73-81. doi: 10.1016/j.ejca.2016.12.020.
Checkpoint inhibition for advanced mucosal melanoma. Thierauf J, Veit JA, Hess J, Treiber N, Lisson C, Weissinger SE, Bommer M, Hoffmann TK. Eur J Dermatol. 2017 Apr 1;27(2):160-165. doi: 10.1684/ejd.2016.2949.
Regulation of submaxillary gland androgen-regulated protein 3A via estrogen receptor 2 in radioresistant head and neck squamous cell carcinoma cells. Grünow J, Rong C, Hischmann J, Zaoui K, Flechtenmacher C, Weber KJ, Plinkert P, Hess J. J Exp Clin Cancer Res. 2017 Feb 6;36(1):25. doi: 10.1186/s13046-017-0496-2.
Expression of Kallikrein-Related Peptidase 6 in Primary Mucosal Malignant Melanoma of the Head and Neck. Thierauf J, Veit JA, Lennerz JK, Weissinger SE, Affolter A, Döscher J, Bergmann C, Knopf A, Grünow J, Grünmüller L, Mauch C, Plinkert PK, Hoffmann TK, Hess J. Head Neck Pathol. 2017 Sep;11(3):314-320. doi: 10.1007/s12105-016-0769-7.
Predictive Factors for Outcome and Quality of Life in HPV-Positive and HPV-Negative HNSCC. Hess J. Recent Results Cancer Res. 2017;206:233-242. doi: 10.1007/978-3-319-43580-0_18.
2017
Upregulation of pAKT(Ser473) expression in progression of HPV-positive oropharyngeal squamous cell carcinoma. Horn D, Freudlsperger C, Holzinger D, Kunzmann K, Plinkert P, Dyckhoff G, Hoffmann J, Freier K, Hess J. Head Neck. 2017 Dec;39(12):2397-2405. doi: 10.1002/hed.24910.
Epithelial-to-Mesenchymal Transition in the Pathogenesis and Therapy of Head and Neck Cancer. Thierauf J, Veit JA, Hess J. Cancers (Basel). 2017 Jul 3;9(7):76. doi: 10.3390/cancers9070076.
Glyoxalase 1 expression is associated with an unfavorable prognosis of oropharyngeal squamous cell carcinoma. Kreycy N, Gotzian C, Fleming T, Flechtenmacher C, Grabe N, Plinkert P, Hess J, Zaoui K. BMC Cancer. 2017 May 26;17(1):382. doi: 10.1186/s12885-017-3367-5.
Human papillomavirus as prognostic marker with rising prevalence in neck squamous cell carcinoma of unknown primary: A retrospective multicentre study. Schroeder L, Boscolo-Rizzo P, Dal Cin E, Romeo S, Baboci L, Dyckhoff G, Hess J, Lucena-Porcel C, Byl A, Becker N, Alemany L, Castellsagué X, Quer M, León X, Wiesenfarth M, Pawlita M, Holzinger D. Eur J Cancer. 2017 Mar;74:73-81. doi: 10.1016/j.ejca.2016.12.020.
Checkpoint inhibition for advanced mucosal melanoma. Thierauf J, Veit JA, Hess J, Treiber N, Lisson C, Weissinger SE, Bommer M, Hoffmann TK. Eur J Dermatol. 2017 Apr 1;27(2):160-165. doi: 10.1684/ejd.2016.2949.
Regulation of submaxillary gland androgen-regulated protein 3A via estrogen receptor 2 in radioresistant head and neck squamous cell carcinoma cells. Grünow J, Rong C, Hischmann J, Zaoui K, Flechtenmacher C, Weber KJ, Plinkert P, Hess J. J Exp Clin Cancer Res. 2017 Feb 6;36(1):25. doi: 10.1186/s13046-017-0496-2.
Expression of Kallikrein-Related Peptidase 6 in Primary Mucosal Malignant Melanoma of the Head and Neck. Thierauf J, Veit JA, Lennerz JK, Weissinger SE, Affolter A, Döscher J, Bergmann C, Knopf A, Grünow J, Grünmüller L, Mauch C, Plinkert PK, Hoffmann TK, Hess J. Head Neck Pathol. 2017 Sep;11(3):314-320. doi: 10.1007/s12105-016-0769-7.
Predictive Factors for Outcome and Quality of Life in HPV-Positive and HPV-Negative HNSCC. Hess J. Recent Results Cancer Res. 2017;206:233-242. doi: 10.1007/978-3-319-43580-0_18.
2016
Affolter, A., M. F. Muller, K. Sommer, A. Stenzinger, K. Zaoui, K. Lorenz, T. Wolf, S. Sharma, J. Wolf, S. Perner, K. J. Weber, K. Freier, P. K. Plinkert, J. Hess and W. Weichert (2016). Targeting irradiation-induced mitogen-activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer. Head Neck Suppl 1:E2049-61.
Dropmann, A., T. Dediulia, K. Breitkopf-Heinlein, H. Korhonen, M. Janicot, S. N. Weber, M. Thomas, A. Piiper, E. Bertran, I. Fabregat, K. Abshagen, J. Hess, P. Angel, C. Coulouarn, D. Steven and N. M. Meindl-Beinker (2016). TGF-beta1 and TGF-beta2 abundance in liver diseases of mice and men. Oncotarget 7(15):19499-518.
Kostareli, E., T. Hielscher, M. Zucknick, L. Baboci, G. Wichmann, D. Holzinger, O. Mucke, M. Pawlita, A. Del Mistro, P. Boscolo-Rizzo, M. C. Da Mosto, G. Tirelli, P. Plinkert, A. Dietz, C. Plass, D. Weichenhan and J. Hess (2016). Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients. Epigenetics 11(1): 61-73.
Tepper, S. R., Z. Zuo, A. Khattri, J. Hess and T. Y. Seiwert (2016). Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas. Oral Oncol 56: 62-70.
Thierauf, J., J. A. Veit, J. Grunow, J. Doscher, S. Weissinger, T. Whiteside, D. Beutner, P. Plinkert, T. K. Hoffmann and J. Hess (2016). Expression of Submaxillary Gland Androgen-regulated Protein 3A (SMR3A) in Adenoid Cystic Carcinoma of the Head and Neck. Anticancer Res 36(2): 611-615.
Zaoui, K., J. Doll, P. Stiebi, P. Federspil, P. K. Plinkert and J. Hess (2016). [Diabetes mellitus as a prognostic marker in oropharyngeal and laryngeal squamous cell carcinoma]. HNO 64(7): 479-486.
Zaoui, K. and J. Hess (2016). [Concepts to improve current treatment regimens in head and neck cancer]. HNO 64(7): 448-449.
2015
Bayo, P., A. Jou, A. Stenzinger, C. Shao, M. Gross, A. Jensen, N. Grabe, C. H. Mende, P. V. Rados, J. Debus, W. Weichert, P. K. Plinkert, P. Lichter, K. Freier and J. Hess (2015). Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma. Mol Oncol 9(8): 1704-1719.
De Ponti, A., L. Wiechert, D. Schneller, T. Pusterla, T. Longerich, N. Hogg, A. Vogel, P. Schirmacher, J. Hess and P. Angel (2015). A pro-tumorigenic function of S100A8/A9 in carcinogen-induced hepatocellular carcinoma. Cancer Lett 369(2): 396-404.
De Ponti, A., L. Wiechert, A. Stojanovic, T. Longerich, S. Marhenke, N. Hogg, A. Vogel, A. Cerwenka, P. Schirmacher, J. Hess and P. Angel (2015). Chronic liver inflammation and hepatocellular carcinogenesis are independent of S100A9. Int J Cancer 136(10): 2458-2463.
Fernandez-Ulibarri, I., K. Hammer, M. A. Arndt, J. K. Kaufmann, D. Dorer, S. Engelhardt, R. E. Kontermann, J. Hess, H. Allgayer, J. Krauss and D. M. Nettelbeck (2015). Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. Int J Cancer 136(9): 2228-2240.
Freudlsperger, C., D. Horn, S. Weissfuss, W. Weichert, K. J. Weber, D. Saure, S. Sharma, G. Dyckhoff, N. Grabe, P. Plinkert, J. Hoffmann, K. Freier and J. Hess (2015). Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma. Int J Cancer 136(12): 2775-2785.
Funk, S., R. Mark, P. Bayo, C. Flechtenmacher, N. Grabe, P. Angel, P. K. Plinkert and J. Hess (2015). High S100A8 and S100A12 protein expression is a favorable prognostic factor for survival of oropharyngeal squamous cell carcinoma. Int J Cancer 136(9): 2037-2046.
George, B., D. Horn, P. Bayo, K. Zaoui, C. Flechtenmacher, N. Grabe, P. Plinkert, V. Krizhanovsky and J. Hess (2015). Regulation and function of Myb-binding protein 1A (MYBBP1A) in cellular senescence and pathogenesis of head and neck cancer. Cancer Lett 358(2): 191-199.
Horn, D., J. Hess, K. Freier, J. Hoffmann and C. Freudlsperger (2015). Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma. Expert Opin Ther Targets 19(6): 795-805.
Leipold, A., J. Hess and K. Zaoui (2015). [The epigenome. Target for innovative therapies in head and neck carcinoma]. HNO 63(11): 786-791.
Schrader, C. H., M. Kolb, K. Zaoui, C. Flechtenmacher, N. Grabe, K. J. Weber, T. Hielscher, P. K. Plinkert and J. Hess (2015). Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients. Mol Cancer 14: 107.
Seidensaal, K., A. Nollert, A. H. Feige, M. Muller, T. Fleming, N. Gunkel, K. Zaoui, N. Grabe, W. Weichert, K. J. Weber, P. Plinkert, C. Simon and J. Hess (2015). Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma. Mol Cancer 14(1): 204.
Thierauf, J., J. A. Veit, A. Affolter, C. Bergmann, J. Grunow, S. Laban, J. K. Lennerz, L. Grunmuller, C. Mauch, P. K. Plinkert, J. Hess and T. K. Hoffmann (2015). Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Res 25(6): 503-509.
Wagner, S., N. Wurdemann, C. Hubbers, M. Reuschenbach, E. S. Prigge, G. Wichmann, J. Hess, A. Dietz, M. Durst, I. Tinhofer, M. von Knebel-Doberitz, C. Wittekindt and J. P. Klussmann (2015). [HPV-associated head and neck cancer : Mutational signature and genomic aberrations]. HNO 63(11): 758-767.
Wichmann, G., M. Rosolowski, K. Krohn, M. Kreuz, A. Boehm, A. Reiche, U. Scharrer, D. Halama, J. Bertolini, U. Bauer, D. Holzinger, M. Pawlita, J. Hess, C. Engel, D. Hasenclever, M. Scholz, P. Ahnert, H. Kirsten, A. Hemprich, C. Wittekind, O. Herbarth, F. Horn, A. Dietz and M. Loeffler (2015). The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer. Int J Cancer 137(12): 2846-2857.
2014
Horwitz, E., I. Stein, M. Andreozzi, J. Nemeth, A. Shoham, O. Pappo, N. Schweitzer, L. Tornillo, N. Kanarek, L. Quagliata, F. Zreik, R. M. Porat, R. Finkelstein, H. Reuter, R. Koschny, T. Ganten, C. Mogler, O. Shibolet, J. Hess, K. Breuhahn, M. Grunewald, P. Schirmacher, A. Vogel, L. Terracciano, P. Angel, Y. Ben-Neriah and E. Pikarsky (2014). Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov 4(6): 730-743.
Schumacher, M., C. Schuster, Z. M. Rogon, T. Bauer, N. Caushaj, S. Baars, S. Szabowski, C. Bauer, M. Schorpp-Kistner, J. Hess, S. Holland-Cunz, E. F. Wagner, R. Eils, P. Angel and B. Hartenstein (2014). Efficient Keratinocyte Differentiation Strictly Depends on JNK-Induced Soluble Factors in Fibroblasts. J Invest Dermatol 134(5): 1332-1341.
Koffler, J., S. Sharma and J. Hess (2014). Predictive value of epigenetic alterations in head and neck squamous cell carcinoma. Mol Cell Oncol 1(2): e954827.
2013
Finimundy, T. C., G. Gambato, R. Fontana, M. Camassola, M. Salvador, S. Moura, J. Hess, J. A. Henriques, A. J. Dillon and M. Roesch-Ely (2013). Aqueous extracts of Lentinula edodes and Pleurotus sajor-caju exhibit high antioxidant capability and promising in vitro antitumor activity. Nutr Res 33(1): 76-84.
Holzinger, D., C. Flechtenmacher, N. Henfling, I. Kaden, N. Grabe, B. Lahrmann, M. Schmitt, J. Hess, M. Pawlita and F. X. Bosch (2013). Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway. Int J Cancer 133(6): 1389-1399.
Koffler, J., D. Holzinger, G. A. Sanhueza, C. Flechtenmacher, K. Zaoui, B. Lahrmann, N. Grabe, P. K. Plinkert and J. Hess (2013). Submaxillary gland androgen-regulated protein 3A expression is an unfavorable risk factor for the survival of oropharyngeal squamous cell carcinoma patients after surgery. Eur Arch Otorhinolaryngol 270(4): 1493-1500.
Kostareli, E., D. Holzinger, O. Bogatyrova, T. Hielscher, G. Wichmann, M. Keck, B. Lahrmann, N. Grabe, C. Flechtenmacher, C. R. Schmidt, T. Seiwert, G. Dyckhoff, A. Dietz, D. Hofler, M. Pawlita, A. Benner, F. X. Bosch, P. Plinkert, C. Plass, D. Weichenhan and J. Hess (2013). HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. J Clin Invest 123(6): 2488-2501.
Leibold, J. S., A. Riehl, J. Hettinger, M. Durben, J. Hess and P. Angel (2013). Keratinocyte-specific deletion of the receptor RAGE modulates the kinetics of skin inflammation in vivo. J Invest Dermatol 133(10): 2400-2406.
Mark, R., J. L. Bermejo, A. Bierhaus, P. K. Plinkert, P. Angel and J. Hess (2013). The receptor for advanced glycation end products is dispensable in a mouse model of oral and esophageal carcinogenesis. Histol Histopathol 28(12): 1585-1594.
Pusterla, T., J. Nemeth, I. Stein, L. Wiechert, D. Knigin, S. Marhenke, T. Longerich, V. Kumar, B. Arnold, A. Vogel, A. Bierhaus, E. Pikarsky, J. Hess and P. Angel (2013). Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice. Hepatology 58(1): 363-373.
2012
Acuna Sanhueza, G. A., L. Faller, B. George, J. Koffler, V. Misetic, C. Flechtenmacher, G. Dyckhoff, P. P. Plinkert, P. Angel, C. Simon and J. Hess (2012). Opposing function of MYBBP1A in proliferation and migration of head and neck squamous cell carcinoma cells. BMC Cancer 12: 72.
Kostareli, E., D. Holzinger and J. Hess (2012). New concepts for translational head and neck oncology: lessons from HPV-related oropharyngeal squamous cell carcinomas. Front Head Neck Cancer 2: 1-10.
Peterziel, H., J. Muller, A. Danner, S. Barbus, H. K. Liu, B. Radlwimmer, T. Pietsch, P. Lichter, G. Schutz, J. Hess and P. Angel (2012). Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation. Neuro Oncol 14(4): 426-439.
Singer, S., R. Zhao, A. M. Barsotti, A. Ouwehand, M. Fazollahi, E. Coutavas, K. Breuhahn, O. Neumann, T. Longerich, T. Pusterla, M. A. Powers, K. M. Giles, P. J. Leedman, J. Hess, D. Grunwald, H. J. Bussemaker, R. H. Singer, P. Schirmacher and C. Prives (2012). Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. Mol Cell 48(5): 799-810.
Wiechert, L., J. Nemeth, T. Pusterla, C. Bauer, A. De Ponti, S. Manthey, S. Marhenke, A. Vogel, U. Klingmuller, J. Hess and P. Angel (2012). Hepatocyte-specific S100a8 and S100a9 transgene expression in mice causes Cxcl1 induction and systemic neutrophil enrichment. Cell Commun Signal 10(1): 40.
2011
Krenzer, S., H. Peterziel, C. Mauch, S. I. Blaber, M. Blaber, P. Angel and J. Hess (2011). Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment. J Invest Dermatol 131(11): 2281-2288.
Lazic, D., F. Alborzi, G. P. Marcuzzi, P. Angel, J. Hess, H. Pfister and B. Akgul (2011). Enhanced StefinA and Sprr2 expression during papilloma formation in HPV8 transgenic mice. J Dermatol Sci 62(2): 84-90.